At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
Pembrolizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab, Irinotecan, and 1 other intervention for High Grade Malignant Neuroendocrine Carcinoma (Diagnosis). Completed, enrolled 36 participants across 3 sites.
Detailed Summary
This is a pilot study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinoma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartJun 2017
Primary CompletionOct 2021
TodayJul 2026
First PostedMay 2, 2017
Enrollment StartJun 20, 2017
Primary CompletionOct 31, 2021
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 9.2 years ago
Interventions
Pembrolizumabdrug
Given Intravenously (IV)
Irinotecandrug
Given IV
Paclitaxeldrug
Given IV